

Exploring new vista for Alzheimer's disease drug targets

Guest Editor: Dileep Kumar**Aims & Scope:**

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease with no substantial treatment. This makes it absolutely crucial to design and develop novel drugs acting upon both new and established drug targets. In the recent years, there has been extensive research on molecular alterations in AD. The scope of this thematic issue is to cover the novel compounds which have an effect on the neurofibrillary tangle hyperphosphorylation, amyloid plaque (A β) accumulation. Additionally, we aim to encompass other novel molecular targets like TREM2, Microglia and related drug developmental insights, that have the potential to hinder the progression of AD. This thematic issue will encompass the role of theoretical studies of different methodologies, such as QSAR, molecular docking, and machine learning-based virtual screening in the pursuit of drug design of novel drug candidates for the treatment of AD. There is an imperative need to design and develop novel antagonists to provide a better perspective of understanding the disease and also present an azure firmament of drug design for its early treatment.

Keywords: Alzheimer's disease, amyloid plaque A β , tau hyperphosphorylation, therapeutics, drug target, drug discovery.

Subtopics:

The subtopics to be covered within this issue include:

- Heterocyclic moiety and their plausible role in AD treatment
- Molecular Docking and Dynamics
- Nano formulation of herbal drugs
- Role of TREM2 in Alzheimer's Disease
- Exploration of Prodrug in the treatment of AD

Schedule:

- ✧ Manuscript submission deadline: 15 March 2022
- ✧ Peer Review Due: 15 April 2022
- ✧ Revision Due: 10 May 2022
- ✧ Announcement of acceptance by the Guest Editors: 5 June 2022
- ✧ Final manuscripts due: 30 June 2022

Contacts:

Guest Editor: Dileep Kumar

Affiliation: Department of Pharmaceutical Chemistry

Poona College of Pharmacy, Bharati Vidyapeeth University, India

Email: dileep.0@gmail.com

Any queries should be addressed to ctmc@benthamscience.net.